Remove 2021 Remove Cannabinoids Remove Epilepsy Remove Treatment
article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.

article thumbnail

United States Minor Cannabinoids (CBG, CBC, CBN, THCV, CBGA) Markets Report 2021-2028 – ResearchAndMarkets.com

Cannabis Law Report

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. minor cannabinoids market size is expected to reach USD 26.2

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Answer of the Day for Jul 23, 2021

TheAnswerPage

Some cannabinoid-based drugs have been approved by national drug administrations. For example, Epidiolex (a CBD product) has been approved by the US FDA for the treatment of rare pediatric seizure disorders (Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex). e58010716930, 2021. GONZAGA, R. DOI: 10.3344.

article thumbnail

Answer of the Day for Jul 6, 2021

TheAnswerPage

There is a high strength of evidence for the efficacy of cannabinoid-based medicines for the treatment of intractable epilepsy, multiple sclerosis and cancer-related nausea. Which of these 3 conditions has the greatest relative number of patients using cannabinoid -based medicines to treat the condition? Schlag, A.K.,

article thumbnail

Report: Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis

Cannabis Law Report

Scientific Reports volume 11 , Article number: 23462 ( 2021 ) Cite this article. Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Metrics details.

Safety 52
article thumbnail

Answer of the Day for Aug 20, 2021

TheAnswerPage

Has any national drug administration approved a CBD-containing product for therapeutic use in conditions other than epilepsy? Regulatory approval has been obtained in numerous countries outside the United States for the treatment of multiple sclerosis symptoms (nerve pain, spasticity, overactive bladder, and other symptoms).

article thumbnail

Answer of the Day for Jun 15, 2021

TheAnswerPage

Has any national drug administration approved a CBD-containing product for therapeutic use in conditions other than epilepsy? Regulatory approval has been obtained in numerous countries outside the United States for the treatment of multiple sclerosis symptoms (nerve pain, spasticity, overactive bladder, and other symptoms).”